Oladapo Afolabi, MD
Nephrology · Fort Worth, TXNPI 1588656391
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.7%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Outset Medical Inc at 45.3% of the total. Reporting peaked in 2022 at $6,760 and has fallen 87.9% since, to $815 in 2025. Among nephrology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 275 payments — averaging $67.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Outset Medical Inc$8K
- Amgen$3K
- Medtronic$2K
- AstraZeneca$2K
- Aurinia Pharma U.S., Inc.$336
- Mallinckrodt Enterprises LLC$245
- plus $3K from 30 others
What the payments were for
- Consulting fees$3,50019%
- Speaking & faculty fees$3,32818%
- Travel & lodging$3,78720%
- Food & beverage$7,72042%
- Education$1261%
- Entertainment$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Outset Medical Inc | 9 | $8,382 |
| Amgen(2 entities) | 56 | $2,832 |
| Medtronic(2 entities) | 27 | $2,497 |
| AstraZeneca | 72 | $1,645 |
| Aurinia Pharma U.S., Inc. | 5 | $336 |
| Mallinckrodt Enterprises LLC | 2 | $245 |
| GSK | 13 | $224 |
| Volta Medical Inc | 1 | $193 |
| Fresenius USA Marketing, Inc. | 7 | $192 |
| W. L. Gore & Associates, Inc. | 3 | $185 |
| Vifor Pharma, Inc. | 8 | $180 |
| Bayer | 8 | $168 |
| Otsuka America Pharmaceutical, Inc. | 7 | $159 |
| Akebia Therapeutics Inc | 8 | $144 |
| Boehringer Ingelheim | 6 | $128 |
| Bard Peripheral Vascular, Inc. | 5 | $109 |
| Daiichi Sankyo Inc. | 5 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $94 |
| OPKO Pharmaceuticals, LLC | 3 | $93 |
| Abbott | 1 | $89 |
| Mallinckrodt Hospital Products Inc. | 3 | $72 |
| Novo Nordisk | 3 | $65 |
| Boston Scientific | 2 | $56 |
| Mozarc Medical US LLC | 2 | $47 |
| Novartis | 2 | $43 |
| Scpharmaceuticals Inc. | 2 | $36 |
| Johnson & Johnson | 2 | $36 |
| Shire North American Group Inc | 1 | $25 |
| Travere Therapeutics, Inc. | 1 | $22 |
| Calliditas Therapeutics US Inc. | 1 | $19 |
| Baxter Healthcare | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| Merck | 1 | $14 |
| Cook Medical LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELLIPSYS VASCULAR ACCESS SYSTEM$1,889
- KRYSTEXXA$1,681
- LUPKYNIS$270
- ACTHAR$245
- LOKELMA$230
- VX1$193
- VIABAHN Endoprosthesis$143
How this compares
$18,510 in reported general payments places this provider in the 90th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 384 | $301,197 |
| KerendiaFinerenone | 87 | $68,446 |
| JardianceEmpagliflozin | 75 | $68,388 |
| VelphoroSucroferric Oxyhydroxide | 23 | $67,854 |
| LokelmaSodium Zirconium Cyclosilicate | 45 | $41,831 |
| AranespDarbepoetin Alfa In Polysorbat | 14 | $40,654 |
| ProcritEpoetin Alfa | 16 | $32,378 |
| EliquisApixaban | 22 | $19,304 |
| Sevelamer Carbonate | 44 | $11,545 |
| DapagliflozinDapagliflozin Propanediol | 11 | $5,817 |
| Torsemide | 77 | $2,616 |
| Calcitriol | 66 | $2,118 |
| Cinacalcet Hcl | 11 | $1,491 |
| Hydralazine Hcl | 79 | $1,413 |
| Midodrine Hcl | 20 | $1,379 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,645 | $343,028429 claims |
| BayerKerendia | $168 | $68,44687 claims |
| Boehringer IngelheimJardiance | $128 | $68,38875 claims |
| Fresenius USA Marketing, Inc.Velphoro | $192 | $67,85423 claims |
| AmgenAranesp | $2,832 | $40,65414 claims |
| Johnson & JohnsonProcrit | $36 | $32,37816 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $16 | $37027 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,070 nephrology providers in Texas.
Other nephrology in Fort Worth
- Saravanan BalamuthusamyFort Worth$435K
- Sandeep ShoriFort Worth$195K
- Michael AragonFort Worth$138K
- Abdul AbdellatifWebster$2.1M
- German HernandezEl Paso$1.3M
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Sreedhar MandayamHouston$752K
- Luis VelezSan Antonio$505K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.